Bio-Connect

Immunoglobulin G3

16-16-090707-3
Athens Research
Product group Proteins / Signaling Molecules
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Athens Research
  • Product Name
    Immunoglobulin G3
  • Delivery Days Customer
    9
  • Applications Supplier
    Inflammation, Biotherapeutics, In Vitro Diagnostic, Wiskott-Aldrich syndrome, Autoimmune Diseases, Infection
  • Certification
    Research Use Only
  • Estimated Purity
    ≥95% by SDS-PAGE
  • Scientific Description
    Serum IgG3, constituting ~6% of total IgG, is distinguished by an elongated 62-amino-acid hinge region stabilized by 11 disulfide bonds, conferring unmatched flexibility for antigen engagement and effector function activation. This subclass exhibits potent complement activation via C1q binding and high-affinity interactions with FcgammaRI/III receptors, surpassing IgG1 in triggering antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. Its extended hinge enhances spatial tolerance for antigen binding, enabling superior neutralization of enveloped viruses like HIV and CHIKV. IgG3 deficiency (less then0.3 g/L) correlates with Wiskott-Aldrich syndrome, systemic lupus erythematosus (SLE), and recurrent bacterial/viral infections due to impaired immune complex clearance. In SLE models, IgG3 deposits drive glomerulonephritis via FcgammaR-mediated neutrophil activation, while its deficiency attenuates renal damage. Paradoxically, early IgG3 responses in acute infections (e.g., CHIKV) correlate with severe initial symptoms but prevent chronic arthralgia by rapid viral clearance. Clinically, IgG3’s short half-life (7 days vs. IgG1’s 21 days) stems from Arg435-mediated FcRn competition, though the H435 allotype extends half-life for therapeutic use. Anti-HIV IgG3 antibodies peak within 4–5 months post-infection, serving as transient biomarkers for recent exposure6. Hinge-length polymorphisms (3 vs. 4 repeats) influence COVID-19 severity, with shorter hinges impairing viral neutralization and increasing mortality risk. Engineered IgG3 variants with stabilized hinges enhance phagocytosis 3-fold, offering promise for antibody therapeutics targeting intracellular pathogens.
  • Shelf life instruction
    more then 1 year
  • Source
    Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
  • Storage Instruction
    +2 - 8° C
  • UNSPSC
    12352202

References

  • Devaux, J. J., et al., (2016), 'Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy', Neurology, 86(9): pp 800-7
    Read this paper
  • Sun, X., et al., (2018), 'Identification and Characterization of Novel Fc-Binding Heptapeptides from Experiments and Simulations', Polymers 10: pp 778
    Read this paper
  • Kruljec, N., et al., (2018), 'Development and Characterization of Peptide Ligands of Immunoglobulin G Fc Region', Bioconjugate Chem. 29: pp 2763−2775.
    Read this paper
  • Bozovičar, K., et al., (2021), 'Focused peptide library screening as a route to a superior affinity ligand for antibody purification', Scientific Reports 11: pp 11650.
    Read this paper
  • Shah, B., et al., (2022), 'Observation of Heavy-Chain C-Terminal Amidation in Human Endogenous IgG', Journal of Pharmaceutical Sciences 111: pp 2445−2450.
    Read this paper